02-Jun-19, The Economic Times
With incipient regulatory changes in China on Indian drug imports, Dr Reddy's Laboratories has identified about 70 products for the country to be launched in a few years and is also planning to build a new plant very close to the existing one.
%20The%20Economic%20Times.jpg "70 products in pipeline Indias Dr Reddys bullish on China (c) The Economic Times")
Image: The Economic Times
Dr Reddy's Chief Operations Officer, Erez Israeli, in a recent earnings call said the drug-maker is in the process of seeking necessary approvals from Chinese authorities for selling drugs including in oncology area there and is upgrading professional teams for the growth.
DRL has a subsidiary Dr Reddy's (WUXI) Pharmaceutical and joint venture Kunshan Rotam Reddy Pharmaceuticals, engaged in manufacturing and marketing of formulations in China.